Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Natera Inc (NTRA)

Natera Inc (NTRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,567,676
  • Shares Outstanding, K 138,321
  • Annual Sales, $ 1,697 M
  • Annual Income, $ -190,430 K
  • EBIT $ -352 M
  • EBITDA $ -321 M
  • 60-Month Beta 1.62
  • Price/Sales 15.17
  • Price/Cash Flow N/A
  • Price/Book 25.68

Options Overview Details

View History
  • Implied Volatility 39.34% (+0.25%)
  • Historical Volatility 31.58%
  • IV Percentile 22%
  • IV Rank 12.03%
  • IV High 86.29% on 04/08/25
  • IV Low 32.92% on 06/16/25
  • Expected Move (DTE 3) 10.12 (4.25%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 259
  • Volume Avg (30-Day) 669
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 12,291
  • Open Int (30-Day) 13,285
  • Expected Range 227.78 to 248.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.50
  • Number of Estimates 5
  • High Estimate -0.28
  • Low Estimate -0.68
  • Prior Year -0.41
  • Growth Rate Est. (year over year) -21.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
221.84 +7.23%
on 12/17/25
256.36 -7.20%
on 01/07/26
+5.94 (+2.56%)
since 12/12/25
3-Month
170.82 +39.27%
on 10/14/25
256.36 -7.20%
on 01/07/26
+63.72 (+36.58%)
since 10/13/25
52-Week
125.38 +89.74%
on 04/07/25
256.36 -7.20%
on 01/07/26
+68.59 (+40.51%)
since 01/13/25

Most Recent Stories

More News
Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling

New AI-derived model integrates longitudinal ctDNA and clinical data with digital pathology and tumor sequencing data, to refine recurrence risk assessment and outcomes prediction

NTRA : 237.89 (+1.04%)
Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA

Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a new collaboration with NVIDIA to accelerate the development of Natera’s multimodal...

NTRA : 237.89 (+1.04%)
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signateraâ„¢ Growth

2025 revenues are expected to increase by approximately 35% compared to 2024, which is approximately $40 million above the top end of Natera’s financial outlook Additional...

NTRA : 237.89 (+1.04%)
2 Cash-Heavy Stocks to Keep an Eye On and 1 We Question

2 Cash-Heavy Stocks to Keep an Eye On and 1 We Question

MCFT : 21.82 (+0.79%)
NTRA : 237.89 (+1.04%)
CPNG : 21.97 (-0.90%)
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

– STELLAR-316 will use Natera’s Signatera™ assay to identify MRD-positive patients for trial enrollment and to monitor response to therapy –

NTRA : 237.89 (+1.04%)
EXEL : 44.08 (+0.05%)
Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI

Study showed a statistically significant disease-free survival (DFS) benefit in all Signatera TM -positive patients following blinded central review

NTRA : 237.89 (+1.04%)
Natera Launches 21-Gene Fetal Focusâ„¢ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNPâ„¢ Technology

Fetal Focus achieved 96% sensitivity and 98% specificity in validation from the prospective blinded EXPAND clinical trial

NTRA : 237.89 (+1.04%)
3 Growth Stocks with Explosive Upside

3 Growth Stocks with Explosive Upside

NTRA : 237.89 (+1.04%)
BE : 139.77 (+2.12%)
MDB : 411.19 (-1.67%)
3 Reasons We’re Fans of Natera (NTRA)

3 Reasons We’re Fans of Natera (NTRA)

NTRA : 237.89 (+1.04%)
3 Market-Beating Stocks Worth Your Attention

3 Market-Beating Stocks Worth Your Attention

NVMI : 404.65 (+0.26%)
NTRA : 237.89 (+1.04%)
DXPE : 113.44 (-1.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California.

See More

Key Turning Points

3rd Resistance Point 249.70
2nd Resistance Point 244.56
1st Resistance Point 241.23
Last Price 237.89
1st Support Level 232.76
2nd Support Level 227.62
3rd Support Level 224.29

See More

52-Week High 256.36
Last Price 237.89
Fibonacci 61.8% 206.33
Fibonacci 50% 190.87
Fibonacci 38.2% 175.41
52-Week Low 125.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar